Investment Bridge, one of Japan's leading IR services companies, has released a
“Bridge Report” on CellSeed Inc. (JASDAQ: 7776) reviewing fiscal year
December 2013 earnings results and fiscal year December 2014 earnings estimates.
* CellSeed believes that regenerative medicine within Japan is entering a period
of full scale development and rapid growth.
* During fiscal year December 2013, sales rose by 40.0% year-over-year to JPY105
million, and the recurring loss declined to JPY581 from JPY842 million in the
* During fiscal year December 2014, CellSeed will continue to pursue progress in
and fortify the three cornerstones of its business based upon its midterm term
vision of “creation of a sustainable business model that leverages changes in
the external environment.”
CellSeed is a leading company in regenerative medicine, which employs the
cutting edge technology of “cell sheet engineering” as its technological
base for developing new medical treatments that can lead to fundamental changes
in the therapy of severe medical conditions worldwide.
About Bridge Report:
Bridge Report is produced by Investment Bridge Co., Ltd. and provides accurate
and objective information about the earnings, business strategies, and other
information of publicly traded Japanese companies.
Investment Bridge Co., Ltd.
Contributed via: Bloomberg Publisher WEB Service
Press spacebar to pause and continue. Press esc to stop.